CRPC w/ Bone Metastases VL

Radiopharmaceuticals in Prostate Cancer - Stefano Fanti

Details
Stefano Fanti, MD. presents "RADIOPHARMACEUTICALS IN PROSTATE CANCER" from the NCCN and EAU guidelines to the new tracers this state of the art lecture is followed with a Q & A with E. David Crawford, MD. Stefano Fanti, MD. Director of Specialty School of Nuclear Medicine at University of Bologna Nuclear Medicine, Associate Professor, University of Bologna, Director of Nuclear Medicine Division an...

Radium-223: Nuclear Medicine Perspective - Phillip Koo

Details
Phillip Koo, MD Associate Professor, Radiology - Nuclear Medicine University of Colorado School of Medicine Aurora, Colorado Dr. Koo is the associate professor of radiology, nuclear medicine at the University of Colorado School of Medicine. He is a graduate of Drexel University College of Medicine and is a Fellow at the Brigham and Women's Hospital/Children's Hospital/Harvard Medical School Progra...

Detection of Metastatic Disease: Review of the RADAR Group Recommendations - Phillip Koo

Details
E. David Crawford and Philip Koo, discuss the detection of mCRPC and recommendations from the RADAR Wrking group recommendations. Phil Koo, MD. reviews the detection of metastatic catration-resistant prostate cancer disease in a Review of the RADAR Group Recommendations. He reviews the use of imaging in the M0 patients, the biochemical recurrect patients and at initial diagnosis. There have been n...

Radium-223 in an International Early Access Program (EAP): Effects of Concomitant Medication on Overall Survival in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Details
Radium-223 in an International Early Access Program (EAP): Effects of Concomitant Medication on Overall Survival in Metastatic Castration-Resistant Prostate Cancer (mCRPC). Presented by: Dr. Fred Saad. Professor and Chief of Urology and Director of GU Oncology at the University of Montreal Hospital Centers, in Montreal, Canada. On behalf of my co-authors, it gives me great pleasure to present the...

Effects of concomitant use of abiraterone and/or enzalutamide with radium-223

Details
Thomas Keane, shares recent data presented at the ECC : Effects of concomitant use of abiraterone and/or enzalutamide with radium-223 on safety and overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients treated in an international early access program (EAP) Thomas E. Keane, MBBCh, FRCSI, FACS, is Professor and Chairman of the Department of Urology at the Medical Unive...

Radium-223 For mCRPC: The Urologist Perspective - Neal Shore

Details
Radium-223 For Metastatic Castration-resistant Prostate Cancer: The Urologist Perspective - Presented by Neal Shore, MD. Radium-223 dichloride (radium-223) is an important therapeutic option for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and no visceral disease. The unique mechanism of action of this first-in-class alpha-emitting radiopharmace...

The Art and Science of Treating CRPC with Bone Metastases - Charles Ryan

Details
The Art and Science of Treating CRPC with bone metastases integrating Radium-223 into treatment - Charles Ryan, MD. presents two patient cases. Charles J. Ryan, MD Professor of Clinical Medicine Division of Hematology / Oncology Helen Diller Family Comprehensive Cancer Center University of California, San Francisco BIOGRAPHY Charles J. Ryan, MD is a Professor of Medicine in the Division of Hematol...

Radium-223 in an Early Access Program: Effects of Concomitant Medication on OS in mCRPC Patients - Thomas Keane

Details
Radium-223 in an International Early Access Program (EAP): Effects of Concomitant Medication on Overall Survival in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Thomas E. Keane, MBBCh, FRCSI, FACS Professor and Chairman of the Department of Urology Medical University of South Carolina, Charleston, SC USA SEE RELATED CONTENT Click HERE to view the poster from ASCO 2015 Click HER...

EBRT Use and Safety with Radium-223 in Patients with CRPC and Bone Metastases from ALSYMPCA - Oliver Sartor

Details
*It is recommended to watch this video in full screen for an optimal viewing experience. EBRT Use and Safety with Radium-223 in Patients with CRPC and Symptomatic Bone Metastases from the ALSYMPCA Trial Professor Sartor presents results from the ALSYMPCA trial which showed radium-223 significantly reduced the risk of EBRT use for bone pain while significantly improving overall survival (OS). Moreo...

Radium-223 Expanded Access Program with Abiraterone and Enzalutamide - Oliver Sartor

Details
*It is recommended to watch this video in full screen for an optimal viewing experience. Prior and Concurrent Use of Abiraterone and Enzalutamide with Radium-223 in US Expanded Access Setting Professor Sartor provides results from the US Expanded Access trial that demonstrates radium-223 concurrently administered with abiraterone acetate or enzalutamide is safe and well tolerated. A. Oliver Sartor...